Literature DB >> 16299526

Viruses - seeking and destroying the tumor program.

Clodagh C O'Shea1.   

Abstract

DNA viruses have enormous utility in cancer research, both as tools for tumor target discovery as well as agents for lytic cancer therapies. This is because there is a profound functional overlap between the DNA viral and tumor cell programs. DNA viruses encode proteins that elicit growth deregulation in infected cells similar to that engendered by mutations in tumor cells. Evolution has refined viral proteins to target the critical cellular hubs that regulate growth. Thus, viral proteins are discriminating biochemical probes that can be used to identify and characterize novel tumor targets. Moreover, the overlap between the DNA viral and tumor programs can also be exploited for the development of lytic cancer therapies. Discovering whether tumor cells selectively complement the replication of viral mutants can reveal novel oncolytic viral therapies, as well as unexpected tumor properties. For example, altered RNA export was recently uncovered as a novel tumor cell property that underlies ONYX-015 replication, a promising oncolytic adenoviral therapy. A perspective is provided on how adenovirus could be systematically exploited to map the requisite role, or indeed the redundancy, of cellular pathways that act in an integrated program to elicit pathological replication. This knowledge has important applications for the rational design of the next generation of oncolytic viruses, as well as the discovery of efficacious combination cancer therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299526     DOI: 10.1038/sj.onc.1209047

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell.

Authors:  Junjie Liu; Lin Fang; Qian Cheng; Liantao Li; Changqing Su; Baofu Zhang; Dongsheng Pei; Jie Yang; Wang Li; Junnian Zheng
Journal:  Cancer Sci       Date:  2012-08-10       Impact factor: 6.716

2.  Viral and Cellular Genomes Activate Distinct DNA Damage Responses.

Authors:  Govind A Shah; Clodagh C O'Shea
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

Review 3.  Viral manipulation of DNA repair and cell cycle checkpoints.

Authors:  Mira S Chaurushiya; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2009-05-26

4.  Use of oncolytic viruses for the eradication of drug-resistant cancer cells.

Authors:  Dominik Wodarz
Journal:  J R Soc Interface       Date:  2009-02-06       Impact factor: 4.118

5.  Cancer: Viruses' backup plan.

Authors:  Kevin M Ryan
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

Review 6.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

7.  ODE models for oncolytic virus dynamics.

Authors:  Natalia L Komarova; Dominik Wodarz
Journal:  J Theor Biol       Date:  2010-01-18       Impact factor: 2.691

8.  A structural basis for the assembly and functions of a viral polymer that inactivates multiple tumor suppressors.

Authors:  Horng D Ou; Witek Kwiatkowski; Thomas J Deerinck; Andrew Noske; Katie Y Blain; Hannah S Land; Conrado Soria; Colin J Powers; Andrew P May; Xiaokun Shu; Roger Y Tsien; James A J Fitzpatrick; Jeff A Long; Mark H Ellisman; Senyon Choe; Clodagh C O'Shea
Journal:  Cell       Date:  2012-10-12       Impact factor: 41.582

9.  Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection.

Authors:  Dominik Wodarz; Natalia Komarova
Journal:  PLoS One       Date:  2009-01-30       Impact factor: 3.240

10.  Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor.

Authors:  J-C Tseng; T Granot; V DiGiacomo; B Levin; D Meruelo
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.